ORASURE TECHNOLOGIES INC (OSUR)
Health Care · medical diagnostics and laboratory services · NASDAQ
OraSure Technologies is a medical diagnostic company dedicated to decentralizing healthcare through rapid, accessible, and point-of-care testing and specimen collection tools.
What ORASURE TECHNOLOGIES INC does
OraSure Technologies develops, manufactures, and markets point-of-care and home diagnostic tests alongside sample management solutions. Its portfolio focuses on decentralizing diagnostics for infectious diseases such as HIV, HCV, syphilis, and sickle cell disease, as well as providing specimen collection devices for research and clinical markets. The company operates through a single integrated business unit to deliver convenient and accessible healthcare solutions globally.
Recent developments
In June 2026, the company received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit. In July 2026, it received FDA Emergency Use Authorization for the OraQuick™ Ebola 2.0 Rapid Antigen Test.
From ORASURE TECHNOLOGIES INC's filing of 2026-08-07.
Themes: point-of-care testing, at-home diagnostics, infectious disease testing, sample management solutions, decentralized healthcare, liquid biopsy, sexual health testing
Fundamentals
- Price$3.86 as of 2026-10-21 close
- Market cap$266M as of 2026-07-31 (share count; price 2026-10-21)
- 1-year return+30.0% 2025-10-21 close $2.97 → 2026-10-21 close $3.86
- P/En/a negative earnings
- Net margin-59.8% FY2025, SEC XBRL
- Gross margin+41.9% FY2025, SEC XBRL
- ROE-20.2% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-38.1% FY2025, SEC XBRL
- Revenue CAGR (3y)-33.3% SEC XBRL
- Beta1.08 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How OSUR compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $31M | $13M | $5M | $6M | $0.09 | -$10M† | $2M† |
| Q1 FY2026 2026-03-31 | $28M | $12M | -$23M | -$22M | -$0.32 | -$14M | $913000 |
| Q4 FY2025 2025-12-31 | $27M† | $11M† | -$20M† | -$19M† | -$0.27† | -$9M† | $922000† |
| Q3 FY2025 2025-09-30 | $27M | $12M | -$16M | -$14M | -$0.19 | -$10M† | $919000† |
| Q2 FY2025 2025-06-30 | $31M | $13M | -$18M | -$20M | -$0.26 | -$10M† | $2M† |
| Q1 FY2025 2025-03-31 | $30M | $12M | -$18M | -$16M | -$0.21 | -$20M | $420000 |
| Q4 FY2024 2024-12-31 | $37M† | $14M† | -$12M† | -$11M† | -$0.14† | $109000† | $456000† |
| Q3 FY2024 2024-09-30 | $40M | $17M | -$6M | -$5M | -$0.06 | $13M† | $145000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$161M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How ORASURE TECHNOLOGIES INC looks technically
ORASURE TECHNOLOGIES INC (OSUR) is trading 12.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 143 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago. It is 15.7% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 12.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +12.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.72 | $3.72 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.44 | $3.44 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 3.63. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 143 trading days ago — a "golden cross", a bullish long-term signal | 143 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 12.3% above | +12.3% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.3 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($3.59 to $4.13) — its "stochastic" reading is 50 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 50.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.58 | $4.58 |
|---|---|---|
| From the 52-week high | it is 15.7% below its 52-week high (its highest price of the past year) | -15.7% |
| Above the 52-week low | it is 85.6% above its 52-week low (its lowest price of the past year) | +85.6% |
| Below the 52-week high | it is 15.7% below its highest point of the past year | 15.7% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day low about 30 trading days ago | 30 sessions |
| All-time high | its highest closing price on record is $23.01 (set on 2017-10-04) | $23.01 |
| Given back of the 52-week move | over the past year its closes ranged ($2.11 to $4.50), and it has given back roughly a quarter of its rise from last year’s low — 27% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.95 to $3.02. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 26.8% |
| From the all-time high | it is 83.2% below its all-time high | -83.2% |
| Nearest price level | it is trading 1.0% above a support level at $3.82 — a price it turned at twice since 2025-01-29, most recently on 2025-07-14. Since 2024-10-21 it has 11 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $2.08 (set on 2025-11-21) | $2.08 |
| Above the all-time low | it is 85.6% above its all-time low | +85.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1553 between its high and its low — about 4.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1553 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.61 and $4.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.61 – $3.84 – $4.07 |
| Typical daily range (% of price) | its price moves about 4.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.0% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (12.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.67× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
1
| Gap at the open | it opened on 2026-10-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +6.93% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.7 percentage points (the stock gained 4.6% while the market lost 0.1%) | +4.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.7 percentage points (the stock gained 1.6% while the market gained 3.3%) | -1.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 12.4 percentage points (the stock gained 22.2% while the market gained 9.8%) | +12.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 14.8 percentage points (the stock gained 30.0% while the market gained 15.2%) | +14.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.5% of the share price. | +1.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.46 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | +11.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $3.74 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +3.2% |
Double top, bearish — forming · entry $3.23 · 55 sessions in
Price levels it has turned at before
OSUR last closed at $3.86 on 2026-10-21. Since 2024-10-21 it has turned at 11 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.82 | Support | 1.0% below the last close | turned there twice · 2025-01-29 to 2025-07-14 |
| $3.92 | Resistance | 1.6% above the last close | turned there three times · 2025-01-07 to 2026-08-24 |
| $3.72 | Support | 3.7% below the last close | turned there five times · 2024-11-19 to 2026-08-12 |
| $4.05 | Resistance | 5.0% above the last close | turned there twice · 2024-11-25 to 2025-02-24 |
| $4.15 | Resistance | 7.5% above the last close | turned there five times · 2024-12-11 to 2026-10-06 |
| $3.52 | Support | 8.7% below the last close | turned there twice · 2025-07-23 to 2025-08-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $3.63.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.61 and $5.22 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $3.63.
This reading has stood for 3 trading days, since 2026-10-19.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Tested and reclaimed 200-day support · trendless / choppy (low ADX) · beating the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$4.00 range $4.00 – $4.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OSUR
- Consensus EPS estimate-$0.18 next reporting period, as of 2026-10-18
- Estimate change, 30 days$0.00 from -$0.18, on 2026-09-13, 35-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High reliance on market acceptance for existing and future products.","Potential for volatility in genomics and diagnostic markets affecting business operations."]
What changed in the latest 10-Q
AI-assisted comparison of OSUR's 10-Q filed 2026-05-08 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Annual Report on Form 10-K filed March 9, 2026; older filing referenced 2024 Annual Report on Form 10-K filed March 7, 2025
- Newer filing adds that Sickle Cell disease testing is included in Company's diagnostic products
- Newer filing adds reference to HCV products sold as OTC test in certain countries
- Newer filing adds disclosure that Company submitted 510(k) to FDA in December 2025 for rapid molecular self-test for CT/NG currently under review
- Newer filing adds disclosure that Company submitted 510(k) to FDA in December 2025 for Colli-Pee at-home urine collection device for sexually transmitted infections currently under review
- Newer filing specifies risk assessment product sales contribution of $1.4 million for three months ended March 31, 2025
- Newer filing adds revenue table footnote (1) including SickleSCAN in Diagnostics products
- Newer filing includes discussion of consolidated gross profit margin increase to 42.3% for Q1 2026 vs 41.1% for Q1 2025
- Newer filing discusses drivers of margin increase: better overhead absorption, improved product mix, higher non-product revenues, offset by increased scrap expense
- Newer filing reports consolidated operating loss of $23.3 million for three months ended March 31, 2026 vs $17.8 million for three months ended March 31, 2025
- Removed:
- Older filing contained 'Recent Developments' section header and BioMedomics acquisition disclosure (signed November 5, 2025, $4.0 million upfront plus contingent consideration); newer filing does not include this section
- Older filing referenced environmental market as customer segment; newer filing omits environmental market reference
- Older filing stated urine collection device 'is in its early stages'; newer filing states 'Initial sales of this product for research use only are occurring'
- Older filing referenced 'Molecular Services' line item in revenue table with $0-$9 thousand for Q3 2024; newer filing does not include this line item
- Older filing included nine-month period data for risk assessment products ($1.9 million and $6.3 million); newer filing focuses only on quarterly comparison
- Reworded:
- Business overview wording changed from 'development, manufacture, marketing and sale' to 'development, manufacture, marketing, sale and distribution'
- Description of HIV products changed from stating products sold 'as a self-test to individuals in a number of other countries, including as an oral swab in-home test for HIV-1 and HIV-2 in Europe' to 'as a self-test to individuals in a number of other countries, including, for the HIV products, as an oral swab in-home test for HIV-1 and HIV-2 in Europe, and for the HCV products, as an OTC test'
- Risk assessment product line description changed from 'discontinued sales...which was completed in the second quarter of 2025' (older) to same language but with additional context about December 2025 FDA submissions in immediately preceding paragraphs
- Notes:
- Older filing text appears truncated at end of operating results section; newer filing also appears truncated mid-sentence in consolidated operating results section, limiting full comparison of operating results discussion
- The two filings compare different quarterly periods (Q1 2026 vs Q3 2025), which affects the nature and scope of changes
- BioMedomics acquisition disclosed in older filing with expected Q4 2025 closing; newer filing (May 2026) does not show acquisition in the excerpted section, but acquisition completion status cannot be determined from provided text
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-163 buys ($224750) · 0 sells — 1 buying insider
Most recent open-market transaction: 2026-05-14. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OSUR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OSUR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,204,515
- Reported value $45,512,135
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about OSUR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
OSUR had 2,930,877 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
OSUR had 4.25% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.52 days to cover at the same settlement.
- Reported short interest (shares) 2,930,877
- Short interest (% of shares outstanding) 4.25%
- Prior settlement (shares) 3,172,198
- Reported change -7.61%
- Days to cover (reported) 4.52
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Abbott Laboratories (ABT)
- Roche (RHHBY)
- Thermo Fisher Scientific (TMO)
- Becton Dickinson (BDX)
- Cepheid (Danaher) (DHR)
- Hologic (HOLX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OSUR vs…
Frequently asked questions
What does ORASURE TECHNOLOGIES INC (OSUR) do?
OraSure Technologies develops, manufactures, and markets point-of-care and home diagnostic tests alongside sample management solutions. Its portfolio focuses on decentralizing diagnostics for infectious diseases such as HIV, HCV, syphilis, and sickle cell disease, as well as providing specimen collection devices for research and clinical markets. The company operates through a single integrated business unit to deliver convenient and accessible healthcare solutions globally.
What sector is ORASURE TECHNOLOGIES INC (OSUR) in?
ORASURE TECHNOLOGIES INC (OSUR) is classified in the Health Care sector. Its industry is medical diagnostics and laboratory services. It trades on NASDAQ.
Who are ORASURE TECHNOLOGIES INC's (OSUR) competitors?
Notable peers of ORASURE TECHNOLOGIES INC (OSUR) include Abbott Laboratories, Roche, Thermo Fisher Scientific, Becton Dickinson and Cepheid (Danaher). This peer set is informational only — not financial advice.
Is ORASURE TECHNOLOGIES INC (OSUR) overbought or oversold right now?
ORASURE TECHNOLOGIES INC (OSUR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OSUR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.